Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | JUN | P05412 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31002408 | 0.79 | JUN (0.36) | LMNAPOLBRAB9AATML3MBTL1 | |
| SCHEMBL23802503 | 0.79 | JUN (0.36) | LMNAPOLBL3MBTL1CYP19A1PLAU | |
| SCHEMBL1403953 | 0.79 | MEN1 (0.36) | JUNNFKB1NFKB2RELA | |
| SCHEMBL19457214 | 0.79 | ALDH1A1 (0.32) | LMNAL3MBTL1 | |
| SCHEMBL2221837 | 0.75 | KDM4E (0.33) | CYP19A1 | |
| SCHEMBL22778781 | 0.75 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL19251523 | 0.75 | TDP1 (0.35) | LMNARAB9AATMCYP19A1 | |
| SCHEMBL823816 | 0.74 | TSHR (0.33) | LMNAPOLBRAB9ATSHRKIF11 | |
| SCHEMBL11394539 | 0.74 | TSHR (0.35) | TSHRJUNNFKB1NFKB2RELA | |
| SCHEMBL279731 | 0.74 | TSHR (0.39) | LMNAPOLBRAB9ATSHRKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-15 | — | — | US | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4448513-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BeiGene Switzerland GmbH (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401514-A | 3, 4-Dihydroisoquinolin-1 (2H) -one derivatives as STING antagonists and uses thereof | 百济神州有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230403927-A1 | AROMATIC COMPOUNDS | UDC IRELAND LTD (IE) | 2023-12-14 | — | — | US | disclosed |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11800787-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2023-10-24 | — | — | US | disclosed |
| WO-2013092616-A1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20100152047-A1 | Piperazine Compounds Whith a Herbicidal Action | BASF SE (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | LMNA 627/4885POLB 10/4885RAB9A 3316/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | LMNA 607/4885POLB 110/4885RAB9A 4468/4885 |
| US-20230403927-A1 | AROMATIC COMPOUNDS | TYR, CTCF, MITF | LMNA 3401/4885POLB 2260/4885RAB9A 2503/4885 |
| US-20100152047-A1 | Piperazine Compounds Whith a Herbicidal Action | CBR3, CBR1, CNPY2 | LMNA 1633/4885POLB 2589/4885RAB9A 2481/4885 |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | P2RX5, P2RX3, ABCG2 | LMNA 2150/4885POLB 2247/4885RAB9A 2252/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | LMNA 1340/4885POLB 2391/4885RAB9A 752/4885 |
| US-20130158004-A1 | Azetidine Derivatives | GPR119, LIPE, LPL | LMNA 3286/4885POLB 4627/4885RAB9A 282/4885 |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | LMNA 2354/4885POLB 1044/4885RAB9A 4576/4885 |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | SELE, SELPLG, SELP | LMNA 2712/4885POLB 4584/4885RAB9A 1624/4885 |
| US-11800787-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | LMNA 4079/4885POLB 1589/4885RAB9A 1927/4885 |
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | STING1, IRF3, MAVS | LMNA 1326/4885POLB 703/4885RAB9A 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.